Biological drug and drug delivery-mediated immunotherapy

Acta Pharmaceutica Sinica B

Chenjie Xu¹  Zhenfeng Wu²  Yi Li³  Qingqing Xiao³  Xiaotong Li³  Wei He⁴  Zhongjian Chen⁴ 

[1] Department of Biomedical Engineering, City University of Hong Kong, Hong Kong 999077, China;Key Laboratory of Modern Preparation of TCM, Ministry of Education, Jiangxi University of Traditional Chinese Medicine, Nanchang 330004, China;School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China;Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai 200443, China;

关键词: Inflammatory diseases;    Cancer immunotherapy;    Atherosclerosis;    Pulmonary artery hypertension;    Biologics;    Adoptive cell transfer;   

DOI  :  

来源: DOAJ

【 摘 要 】

The initiation and development of major inflammatory diseases, i.e., cancer, vascular inflammation, and some autoimmune diseases are closely linked to the immune system. Biologics-based immunotherapy is exerting a critical role against these diseases, whereas the usage of the immunomodulators is always limited by various factors such as susceptibility to digestion by enzymes in vivo, poor penetration across biological barriers, and rapid clearance by the reticuloendothelial system. Drug delivery strategies are potent to promote their delivery. Herein, we reviewed the potential targets for immunotherapy against the major inflammatory diseases, discussed the biologics and drug delivery systems involved in the immunotherapy, particularly highlighted the approved therapy tactics, and finally offer perspectives in this field.

【 授权许可】

Unknown